mProX™ Human TACSTD2 Stable Cell Line

Product Information

Target Family

Other Targets

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;MCF-7;MCF-7/TMX2

Target Classification

Other Targets Drug Discovery Assays and Products

Target Research Area

CNS Research;Ocular Research

Related Diseases

Corneal Dystrophy, Gelatinous Drop-Like; Lattice Corneal Dystrophy

Gene ID

Human:4070

UniProt ID

Human:P09758

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

TACSTD2, also known as Trop-2, is a transmembrane glycoprotein that has been studied in various contexts. In the context of polycystic ovary syndrome (PCOS), TACSTD2 has been identified as a potential biomarker for diagnosis and treatment. It has been found to be differentially methylated and expressed in ovarian granulosa cells of PCOS patients compared to healthy controls. TACSTD2 has also been implicated in early luminal-like breast cancer, where it is highly expressed. In systemic lupus erythematosus (SLE), TACSTD2 has been identified as one of the differentially expressed genes associated with disease severity. Additionally, TACSTD2 has been studied in high-grade serous ovarian carcinoma (HGSOC), where it has been identified as a specific protein marker in cancer cell-derived extracellular vesicles. Furthermore, TACSTD2 has been investigated in the context of rare diseases, such as gelatinous droplike corneal dystrophy (GDLD), where modulation of the UDP-glucose glycoprotein glucosyl-transferase (UGGT) pathway, which involves TACSTD2, has shown potential as a therapeutic strategy. Overall, TACSTD2 has been implicated in various diseases and has potential as a diagnostic and therapeutic target.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human TACSTD2 Stable Cell Line (S01YF-1023-PY290). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Casey Williams (Verified Customer)

What is the role of TACSTD2 in breast cancer progression? May 20 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

TACSTD2 expression in breast cancer is associated with the expression of genes involved in epithelial transformation, adhesion, and proliferation, contributing to tumor growth. May 20 2020

chat Jordan Smith (Verified Customer)

How does TACSTD2 methylation relate to renal cell cancer progression? Oct 28 2023

chat Patrick Liam (Creative Biolabs Scientific Support)

TACSTD2 methylation is associated with disease progression and clinical course in renal cell carcinoma, suggesting its potential as a biomarker. Oct 28 2023

Published Data

Fig.1 A slight increase in proliferation was observed when TACSTD2 was knocked down in MCF7.

TACSTD2 mRNA expression was assessed by RT-qPCR in technical triplicate for MCF7 (non-transfected), MCF7-Control, MCF7-TACSTD2-Knockdown, TMX2-28 (non-transfected), TMX2-28-Control, and TMX2-28-TACSTD2 cell lines, with statistical significance observed (**p < 0.001). Cell proliferation in MCF7-TACSTD2-Kd and TMX2-28-TACSTD2 cell lines (n = 16) was quantified using the MTS assay, with results expressed as a percentage of control for each respective cell line (***p < 0.0001).

Ref: Zimmers, Stephanie M., et al. "TROP2 methylation and expression in tamoxifen-resistant breast cancer." Cancer cell international 18 (2018): 1-14.

Pubmed: 30002602

DOI: 10.1186/s12935-018-0589-9

Research Highlights

Zhang, Fei. et al. "Analysis of Methylome, Transcriptome, and Lipid Metabolites to Understand the Molecular Abnormalities in Polycystic Ovary Syndrome." Diabetes, metabolic syndrome and obesity : targets and therapy, 2023.
The aim of this study was to identify differentially methylated genes (DMGs) and differentially expressed genes (DEGs) in order to identify potential biomarkers for the diagnosis and treatment of polycystic ovary syndrome (PCOS). Utilizing specific methods and techniques, the researchers sought to uncover valuable insights into the genetic expression and regulation in individuals with PCOS. By identifying potential biomarkers, the study aims to contribute to the development of improved diagnostic and treatment strategies for PCOS.
Zhang, Fei. et al. "Analysis of Methylome, Transcriptome, and Lipid Metabolites to Understand the Molecular Abnormalities in Polycystic Ovary Syndrome." Diabetes, metabolic syndrome and obesity : targets and therapy, 2023.
Pubmed: 37720421 DOI: 10.2147/DMSO.S421947

C Coelho, Rafael. et al. "Trop-2 Is Highly Expressed in Early Luminal-Like Breast Cancer." The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society, 2023.
The transmembrane glycoprotein Trop-2 has been found in human epithelial cells to play a role in breast cancer (BC) tumor growth and prognosis. A cross-sectional study was conducted to assess the expression of Trop-2 protein with immunohistochemistry (IHC) and its correlation with clinicopathological features in early luminal-like BC. Tissue microarrays were used to evaluate Trop-2 expression and categorized into low, intermediate, and high levels using the H-score. The study included 84 patients with a median age of 57, and Trop-2 expression was high in 56% of patients. Results showed no correlation between Trop-2 expression and various clinicopathological features. It was concluded that Trop-2 is highly expressed in early luminal-like BC, regardless of clinicopathological characteristics.
C Coelho, Rafael. et al. "Trop-2 Is Highly Expressed in Early Luminal-Like Breast Cancer." The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society, 2023.
Pubmed: 37675806 DOI: 10.1369/00221554231195659